Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 3 open-market purchases and 0 sales; 171 institutions reported holding it in 13F filings for Q3 2026, worth $167.0M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:19 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 6, 2026 | Jan 8, 2025 | Jan 5, 2024 | – | – |
| Revenue | $0 | $850.0K | – | – | – |
| Operating expenses | $72.8M | $57.5M | $50.4M | $41.7M | $81.9M |
| Research and development | $56.0M | $42.3M | $38.1M | $30.0M | $20.3M |
| Selling, general and administrative | $16.9M | $15.1M | $12.2M | $11.7M | $10.9M |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | -$81.9M |
| Interest expense | – | – | – | $0 | $370.0K |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | -$82.2M |
| EPS, basic | $-0.42 | $-0.36 | $-0.33 | $-0.37 | – |
| Weighted shares, basic | 157.7M | 137.4M | 127.0M | 105.2M | – |
| Margins and growth | |||||
| Operating margin | – | -6661.8% | – | – | – |
| Net margin | – | -5808.8% | – | – | – |
| Revenue growth, year over year | −100.0% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 6, 2026 | Jan 8, 2025 | Jan 5, 2024 | – | – |
| Cash and equivalents | $30.6M | $43.5M | $24.2M | $34.9M | $144.5M |
| Short-term investments | $178.3M | $83.2M | $128.2M | $151.7M | – |
| Total current assets | $209.8M | $132.8M | $153.9M | $194.8M | $147.1M |
| Property, plant and equipment | $102.0K | $353.0K | $898.0K | $1.57M | $2.24M |
| Total assets | $219.6M | $140.4M | $156.9M | $199.6M | $153.8M |
| Accounts payable | $1.58M | $2.25M | $4.09M | $3.38M | $867.0K |
| Short-term debt | – | – | – | – | $0 |
| Total current liabilities | $14.0M | $8.87M | $7.80M | $16.2M | $10.6M |
| Long-term debt | – | – | – | – | $0 |
| Total liabilities | $22.8M | $15.2M | $8.34M | $18.0M | $13.7M |
| Shareholders' equity | $196.8M | $125.2M | $148.5M | $181.6M | $140.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 6, 2026 | Jan 8, 2025 | Jan 5, 2024 | – | – |
| Operating cash flow | -$49.1M | -$44.9M | -$40.6M | -$34.1M | -$19.7M |
| Capital expenditures | $25.0K | $44.0K | $30.0K | $212.0K | $1.57M |
| Free cash flow | -$49.2M | -$44.9M | -$40.6M | -$34.3M | -$21.2M |
| Depreciation and amortization | $276.0K | $589.0K | $699.0K | $782.0K | $600.0K |
| Stock-based compensation | $8.37M | $8.56M | $6.12M | $5.33M | $4.03M |
| Investing cash flow | -$93.3M | $46.8M | $27.0M | -$151.2M | -$1.77M |
| Financing cash flow | $129.6M | $17.3M | $2.94M | $75.8M | $118.6M |
| Net change in cash | -$12.8M | $19.3M | -$10.7M | -$109.6M | $97.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | 1007.1% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 180.1M | +1.3% | SEC |
| Jul 28, 2026 | 180.1M | +30.2% | SEC |
| Apr 30, 2026 | 180.1M | +30.2% | SEC |
| Feb 27, 2026 | 180.1M | +30.2% | SEC |
| Oct 30, 2025 | 177.9M | +29.3% | SEC |
| Aug 4, 2025 | 138.3M | +0.5% | SEC |
| Apr 28, 2025 | 138.3M | +0.5% | SEC |
| Feb 15, 2025 | 138.3M | +0.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.